High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma. 1994

B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
Pediatric Department, University of Essen, Germany.

Twenty-six children with advanced neuroblastoma were consolidated with cisplatin, BCNU, etoposide, melphalan, 21 Gy of local radiotherapy, and bone marrow rescue in a multicenter study. All patients were over 1 year of age at diagnosis. Twenty-two patients were treated in first complete or partial remission and four in second complete or partial remission. Hematologic rescue was autologous (n = 23), allogeneic (n = 2), or syngeneic (n = 1). Extrahematological toxicity involved primarily the gastrointestinal mucosa. Among five fatal toxicities, three included intestinal hemorrhage. Fourteen patients relapsed after BMT, four of them at the primary site. Seven children survive progression-free after 16-56 months. These results are essentially not different from a single-center study with the same protocol or from other published studies. The value of megatherapy for patients with advanced neuroblastoma or for a subgroup of them can only be established on a larger number of patients than most national trials accrue.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D011882 Radiotherapy, High-Energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle. Megavolt Radiotherapy,High-Energy Radiotherapy,Radiotherapy, Megavolt,High Energy Radiotherapy,Radiotherapy, High Energy
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
January 1993, European journal of cancer (Oxford, England : 1990),
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
January 1992, European journal of cancer (Oxford, England : 1990),
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
March 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
January 1992, European journal of cancer (Oxford, England : 1990),
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
April 2000, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
January 1986, Cancer chemotherapy and pharmacology,
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
February 1982, Cancer treatment reports,
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
January 1993, European journal of cancer (Oxford, England : 1990),
B Kremens, and T Klingebiel, and F Herrmann, and C Bender-Götze, and S Burdach, and W Ebell, and W Friedrich, and E Koscielniak, and H Schmid, and W Siegert
December 1989, Bone marrow transplantation,
Copied contents to your clipboard!